Monoamine Oxidase A (MAO-A) Inhibitor Screening Fluorogenic Assay Kit

Monoamine Oxidase A (MAO-A) Inhibitor Screening Fluorogenic Assay Kit is designed to measure human MAO-A activity for screening and profiling applications based on the fluorometric detection of H2O2, one of the byproducts generated during the oxidative deamination of MAO-A substrates. The assay kit comes in a convenient 96-well format, with enough purified MAO-A enzyme, substrate, HydroRed Probe, HydroRed Developer, and assay buffer for 100 enzyme reactions. Figure 1: Mechanism of action of Monoamine Oxidase A (MAO-A) Inhibitor Screening Fluorogenic Assay Kit.Monoamine Oxidase A (MAO-A) catalyzes the oxidative deamination of a primary amine substrate in the presence of oxygen and water. The byproduct hydrogen peroxide (H2O2) generated during the MAO-A reaction serves as a substrate for the downstream HydroRed Developer reaction, which oxidizes the HydroRed Probe to produce a strong fluorescence product, resorufin. The resulting fluorescence intensity is directly proportional to MAO-A enzyme activity. Need us to run inhibitor screens or profile your compounds against MAO-A? Check out our Metabolic Enzyme Screening & Profiling. . Monoamine oxidase (MAO) is an enzyme on the mitochondrial outer membrane that catalyzes the deamination of biogenic and xenobiotic amines, such as neuroactive serotonin, noradrenaline and dopamine. MAO exists in two isoforms, MAO-A and MAO-B. MAO-A, primarily located in the intestinal tract, the liver, and peripheral adrenergic neurons, regulates mood-related neurotransmitters and is a key target for antidepressants and anxiolytics. Beyond its role in mental health, MAO-A contributes to oxidative stress in cardiac tissue, producing hydrogen peroxide that can damage mitochondria and lead to heart failure. Inhibitors may therefore prove beneficial in the treatment of cardiovascular diseases. High level expression of MAO-A is also linked to prostate cancer, where inhibition reduces proliferation in androgen-sensitive and androgen-resistant cells. Thus, MAO-A inhibitors hold therapeutic potential for depression, anxiety, heart failure, and certain cancers, making them an important focus for drug discovery.